Investigating how BACH1 affects lactate processing in triple negative breast cancer
Understanding lactate catabolism by BACH1 in triple negative breast cancer
This study is looking at how a protein called BACH1 affects the way triple negative breast cancer cells use energy, with the goal of making these cells more responsive to treatments that target their metabolism, which could lead to better therapies for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10896936 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of BACH1, a key regulator of metabolism, in triple negative breast cancer (TNBC). The study aims to reduce metabolic variability among cancer cells by targeting BACH1 to enhance the effectiveness of metabolic inhibitors. By depleting BACH1, researchers hope to make TNBC cells more sensitive to treatments that target mitochondrial metabolism, particularly by improving lactate catabolism. This approach could lead to more effective therapies for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from novel metabolic therapies.
Not a fit: Patients with non-triple negative breast cancer types are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with triple negative breast cancer by making their tumors more responsive to existing therapies.
How similar studies have performed: Previous studies have shown promise in targeting metabolic pathways in cancer, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Lee, Jiyoung — George Washington University
- Study coordinator: Lee, Jiyoung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.